CSL announces major manufacturing expansion in Melbourne

CSL announces major manufacturing expansion in Melbourne

Melbourne, Australia — 08/10/2014

CSL Limited (ASX:CSL) today announced a $210 million expansion of its CSL Behring manufacturing site in Broadmeadows (Melbourne) to help meet growing demand for its global critical care therapy, albumin.

The investment will fund a new manufacturing facility on the site, creating 200 jobs during construction and a further 190 highly skilled manufacturing jobs once the plant is fully operational.

Albumin is the most abundant protein in human plasma. It is used to restore blood volume in people following trauma or major surgery, and to support patients with extensive burns or serious infections.

CSL’s global albumin product is currently manufactured by CSL Behring’s US, German and Swiss facilities using plasma collected by CSL Plasma’s international collection centres. The new facility at Broadmeadows will become an integral part of this global supply chain and will have the capacity to make a significant contribution to CSL’s total global albumin output.

As part of CSL’s ongoing expansion strategy, the Company chose to add albumin manufacturing capacity at Broadmeadows following a competitive review of all CSL Behring sites within its global network. A strategic contribution from the Victorian Government was instrumental to the success of the Broadmeadows bid.

“CSL has grown to become a leading global provider of innovative treatments for people with rare and serious diseases. Ensuring we have the capacity to meet the needs of patients well into the future is critical to our continued growth and success”, said CSL’s Chief Executive Officer, Paul Perreault.

“CSL is proud to partner with the Victorian Government in undertaking this next important phase of expansion. The investment will generate significant economic returns for Victoria and further strengthen the role of the Broadmeadows site in our global manufacturing network"’.

The Broadmeadows site currently employs 650 highly skilled workers and is unique in Australia.

It is home to Australia’s only plasma manufacturing facility and is contracted by the Federal Government to supply a broad range of high quality plasma products for patients in Australia. CSL Behring works closely with the National Blood Authority and Australian Red Cross Blood Service to support Australia’s goal of self-sufficiency in plasma products. It also provides a similar service to several other countries in the Asia Pacific region.

In 2012 CSL integrated the Broadmeadows site with the CSL Behring global network. It recently opened on the site a new biotech facility for novel product development and will soon open an adjacent plant to manufacture CSL’s global immune disorder therapy for export markets. These facilities represent an investment of more than $250m and were supported by previous strategic grants from the Victorian and Federal governments.

The new facility will comprise two manufacturing modules. Construction of the first module will begin in the next several weeks and will take about 4 years to complete. At full capacity, CSL estimates the annual commercial value of the albumin to be exported from the facility could be approximately $US600m.


Media Contacts

Sharon McHale
Senior Director Public Affairs
CSL Limited
Phone: +61 409 978 314
Email: sharon.mchale@csl.com.au

Angus Urquhart
Hinton & Associates
Phone: +61 402 575 684
Email: aurquhart@hintons.com.au

Download this release: 
PDF icon CSL announces major manufacturing expansion in Melbourne

© 2017 CSL Limited